Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Sep;20(5):472-8.
doi: 10.1097/MCP.0000000000000080.

Morbidity and mortality in sarcoidosis

Alicia K Gerke  1
Affiliations
Review

Morbidity and mortality in sarcoidosis

Alicia K Gerke. Curr Opin Pulm Med. 2014 Sep.

Abstract

Purpose of review: Chronic sarcoidosis is a complex disease with numerous comorbid conditions and can be fatal in some cases. Recognizing causes of morbidity and mortality is important to effectively select treatments, manage symptoms and improve outcomes. The purpose of this review is to examine emerging knowledge on morbidity and mortality in sarcoidosis.

Recent findings: Approximately 1-5% of patients with sarcoidosis die from complications of sarcoidosis. Recent population studies indicate that mortality may be increasing over the past decade. The reasons behind these trends are unclear, but could include increasing incidence, detection rates, severity of disease or age of the population. Morbidity of sarcoidosis is reflected by a trend of increased hospitalizations over recent years and increased use of healthcare resources. Morbidity can be caused by organ damage from granulomatous inflammation, treatment complications and psychosocial effects of the disease. Recent studies are focused on morbidity related to cardiopulmonary complications, bone health and ageing within the sarcoidosis population. Last, sarcoidosis is associated with autoimmune diseases, pulmonary embolism and malignancy; however, the underlying mechanisms linking diseases continue to be debated.

Summary: Morbidity in sarcoidosis is significant and multifactorial. Mortality is infrequent, but may be increasing over the years.

PubMed Disclaimer

Conflict of interest statement

The author has no conflicts of interest.

References

    1. Gribbin J, Hubbard RB, Le Jeune I, et al. Incidence and mortality of idiopathic pulmonary fibrosis and sarcoidosis in the UK. Thorax. 2006;61(11):980–5. - PMC - PubMed
    1. Reich JM. Mortality of intrathoracic sarcoidosis in referral vs population-based settings: influence of stage, ethnicity, and corticosteroid therapy. Chest. 2002;121(1):32–9. - PubMed
    1. Nicholson TT, Plant BJ, Henry MT, Bredin CP. Sarcoidosis in Ireland: regional differences in prevalence and mortality from 1996–2005. Sarcoidosis Vasc Diffuse Lung Dis. 2010;27(2):111–20. - PubMed
    1. Swigris JJ, Olson AL, Huie TJ, Fernandez-Perez ER, et al. Sarcoidosis-related mortality in the United States from 1988 to 2007. Am J Respir Crit Care Med. 2011;183(11):1524–30. - PMC - PubMed
    1. Duncan ME, Goldacre MJ. Mortality trends for tuberculosis and sarcoidosis in English populations, 1979–2008. Int J Tuberc Lung Dis. 2012;16(1):38–42. - PubMed

Publication types